AR097963A1 - Antagonistas de receptor ep3 de prostaglandina - Google Patents
Antagonistas de receptor ep3 de prostaglandinaInfo
- Publication number
- AR097963A1 AR097963A1 ARP140103751A ARP140103751A AR097963A1 AR 097963 A1 AR097963 A1 AR 097963A1 AR P140103751 A ARP140103751 A AR P140103751A AR P140103751 A ARP140103751 A AR P140103751A AR 097963 A1 AR097963 A1 AR 097963A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkyl
- independently
- antagonists
- prostaglandina
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101150053131 PTGER3 gene Proteins 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888822P | 2013-10-09 | 2013-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097963A1 true AR097963A1 (es) | 2016-04-20 |
Family
ID=51900918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103751A AR097963A1 (es) | 2013-10-09 | 2014-10-08 | Antagonistas de receptor ep3 de prostaglandina |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9278953B2 (enExample) |
| EP (1) | EP3055300B1 (enExample) |
| JP (1) | JP6348582B2 (enExample) |
| AR (1) | AR097963A1 (enExample) |
| CA (1) | CA2926568C (enExample) |
| ES (1) | ES2665153T3 (enExample) |
| TW (1) | TW201527297A (enExample) |
| UY (1) | UY35776A (enExample) |
| WO (1) | WO2015052610A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3237401B1 (en) * | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10336701B2 (en) * | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| SG11202010679SA (en) * | 2018-05-17 | 2020-11-27 | Bayer Ag | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| EP4319734A2 (en) | 2021-04-07 | 2024-02-14 | Hadasit Medical Research Services&Development Ltd. | Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US20080200568A1 (en) | 2005-08-30 | 2008-08-21 | Stephanie Chissoe | Genes Associated With Type ll Diabetes Mellitus |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2014
- 2014-09-25 ES ES14799209.3T patent/ES2665153T3/es active Active
- 2014-09-25 JP JP2016520627A patent/JP6348582B2/ja not_active Expired - Fee Related
- 2014-09-25 WO PCT/IB2014/064836 patent/WO2015052610A1/en not_active Ceased
- 2014-09-25 CA CA2926568A patent/CA2926568C/en not_active Expired - Fee Related
- 2014-09-25 EP EP14799209.3A patent/EP3055300B1/en not_active Not-in-force
- 2014-10-06 TW TW103134754A patent/TW201527297A/zh unknown
- 2014-10-06 US US14/506,752 patent/US9278953B2/en not_active Expired - Fee Related
- 2014-10-08 UY UY0001035776A patent/UY35776A/es not_active Application Discontinuation
- 2014-10-08 AR ARP140103751A patent/AR097963A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9278953B2 (en) | 2016-03-08 |
| CA2926568A1 (en) | 2015-04-16 |
| ES2665153T3 (es) | 2018-04-24 |
| US20150099782A1 (en) | 2015-04-09 |
| EP3055300A1 (en) | 2016-08-17 |
| JP6348582B2 (ja) | 2018-06-27 |
| TW201527297A (zh) | 2015-07-16 |
| CA2926568C (en) | 2017-09-05 |
| EP3055300B1 (en) | 2018-03-07 |
| JP2016532647A (ja) | 2016-10-20 |
| WO2015052610A1 (en) | 2015-04-16 |
| UY35776A (es) | 2015-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124061T1 (el) | Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| SV2017005472A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2023001369A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CR20140301A (es) | Derivados de betulina | |
| EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2016006199A (es) | Inhibidores de replicacion del virus de influenza. | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| DOP2018000196A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2 | |
| EA201690268A1 (ru) | Замещенные производные хиназолин-4-она | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| ECSP14013239A (es) | Composiciones farmacéuticas | |
| BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
| AR094959A1 (es) | Compuestos de imidazo piridina | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| MX2014003169A (es) | Ligandos del receptor ep1. | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| EA201591628A1 (ru) | Дейтерированный палбоциклиб | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| MX2016000188A (es) | Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |